Prime Medicine, Inc. Common Stock (NASDAQ:PRME) — Market Cap & Net Worth
Market Cap & Net Worth: Prime Medicine, Inc. Common Stock (PRME)
Prime Medicine, Inc. Common Stock (NASDAQ:PRME) has a market capitalization of $595.69 Million ($595.69 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11646 globally and #2791 in its home market, demonstrating a -11.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prime Medicine, Inc. Common Stock's stock price $3.41 by its total outstanding shares 180510658 (180.51 Million). Analyse PRME cash generation efficiency to see how efficiently the company converts income to cash.
Prime Medicine, Inc. Common Stock Market Cap History: 2022 to 2026
Prime Medicine, Inc. Common Stock's market capitalization history from 2022 to 2026. Data shows change from $3.35 Billion to $615.54 Million (-34.71% CAGR).
Index Memberships
Prime Medicine, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #304 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1126 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.04% | #176 of 263 |
Weight: Prime Medicine, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prime Medicine, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prime Medicine, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
176.70x
Prime Medicine, Inc. Common Stock's market cap is 176.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.35 Billion | $5.21 Million | -$121.82 Million | 643.74x | N/A |
| 2024 | $527.09 Million | $2.98 Million | -$195.88 Million | 176.70x | N/A |
Competitor Companies of PRME by Market Capitalization
Companies near Prime Medicine, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Prime Medicine, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Prime Medicine, Inc. Common Stock Historical Marketcap From 2022 to 2026
Between 2022 and today, Prime Medicine, Inc. Common Stock's market cap moved from $3.35 Billion to $ 615.54 Million, with a yearly change of -34.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $615.54 Million | -1.73% |
| 2025 | $626.37 Million | +18.84% |
| 2024 | $527.09 Million | -67.04% |
| 2023 | $1.60 Billion | -52.31% |
| 2022 | $3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Prime Medicine, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $595.69 Million USD |
| MoneyControl | $595.69 Million USD |
| MarketWatch | $595.69 Million USD |
| marketcap.company | $595.69 Million USD |
| Reuters | $595.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more